Ventus Therapeutics Inc.

Ventus Therapeutics Inc. , based in Canada, focuses on developing innovative therapeutics targeting biologically validated drug targets that have been considered undruggable. Their advanced technologies drive their mission to improve treatment options. Ventus Therapeutics Inc.

specializes in the development of novel therapeutics aimed at challenging drug targets. Founded in 2019 and headquartered in Montreal, Canada, the company has completed 3 deals, with their most recent funding round occurring on February 9, 2022. The company successfully raised USD 140. 00 mn in Series C funding, co-led by SB Investment Advisers and RA Capital.

The CEO, Marcelo Bigal, has a history of leadership in the pharmaceutical industry, although no prior company founding details are provided. Ventus Therapeutics specializes in developing differentiated therapeutics targeting biologically validated drug targets that have traditionally been seen as undruggable. Their primary products include VENT-02, a brain-penetrant NLRP3 inhibitor currently in Phase 2 trials for Parkinson’s disease, and VENT-03, a first-in-class cGAS inhibitor set to enter Phase 2 development for lupus in 2025. The ReSOLVE® platform supports these initiatives, utilizing artificial intelligence, machine learning, protein science, structural biology, and biophysics to enhance small-molecule drug discovery.

Their primary customers are healthcare providers and patients, particularly in North America, especially the United States and Canada. Ventus Therapeutics generates revenue through collaborations and partnerships focused on drug development. Their business model includes partnerships with pharmaceutical companies and research institutions that provide funding for clinical trials in exchange for commercial rights or profit-sharing agreements. The firm may also engage in collaborations that involve milestone payments tied to specific regulatory or clinical achievements, as well as licensing agreements once products receive regulatory approval.

Following its USD 140. 00 mn Series C funding round in February 2022, Ventus Therapeutics plans to use the investment to enhance its ReSOLVE platform by automating processes, expanding machine learning capabilities, and building larger proprietary virtual libraries. The company is set to launch VENT-03 for lupus by 2025, targeting further advancements in their therapeutic offerings. Ventus aims to expand its presence within the North American market, with a focus on the United States and Canada, aligning with their ongoing commitment to address critical gaps in therapeutic options.